Denali Therapeutics

#AI / data analytics / healthtech / informatics #ALS #Alzheimer's #Axol Bioscience #Biologics #Centessa Pharmaceuticals #Corcept Therapeutics #Denali Therapeutics #Eli Lilly #FDA #Hunter Syndrome #LifeArc #Mergers and acquisitions #MND #Ovarian cancer #Stanford University

DDW Highlights: 7 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, there were crucial developments in neuroscience drug discovery. Elsewhere, a new treatment for… Read More

#Podcasts

Human brain
#Biologics #Denali Therapeutics #FDA #Hunter Syndrome

FDA approves Denali’s Hunter syndrome treatment

The US Food and Drug Administration (FDA) has granted accelerated approval for Avlayah (tividenofusp alfa-eknm), the first FDA-approved biologic specifically designed to cross the blood-brain barrier.   Avlayah is an enzyme replacement therapy indicated for the treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II, or MPS II) when initiated… Read More

#News #Regulatory

Esther Sammler
#Biogen #Clinical trial #Denali Therapeutics #Neurodegenerative disorders #Parkinson's #University of Dundee

New trial will investigate LRRK2 inhibitors for Parkinson’s

A study that could lead to the development of new treatments for Parkinson’s disease has launched at the University of Dundee, Scotland. The study is utilising LRRK2 inhibitors developed by Denali Therapeutics and Biogen. Mutations in the LRRK2 protein kinase are the most frequent cause of… Read More

#Editor's Choice #News